SCHEMBL6761434

SCHEMBL6761434

CCCCC(=O)Oc1c(O)cc(C(=O)OC)c(C(=O)CCCC)c1OC(=O)CCCC

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 1/20 0.40
▸ PLA2G2A P14555 1/20 0.40
▸ PLA2G5 P39877 1/20 0.40
▸ MEN1 O00255 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ PAK1 Q13153 1/20 0.39
▸ HTT P42858 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ MAPT P10636 1/20 0.38
▸ ATM Q13315 1/20 0.38
▸ KDM4E B2RXH2 2/20 0.37
▸ RECQL P46063 1/20 0.37
▸ NR4A1 P22736 1/20 0.37
▸ CNR2 P34972 1/20 0.35
▸ ELANE P08246 2/20 0.35
▸ PTPN1 P18031 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6766244 0.96 PLA2G2A (0.46) FFAR1PLA2G2APLA2G5MEN1KMT2A
SCHEMBL6762804 0.95 PLA2G2A (0.48) FFAR1PLA2G2APLA2G5MEN1KMT2A
SCHEMBL6762243 0.90 TDP1 (0.43) FFAR1PLA2G2APLA2G5MEN1KMT2A
SCHEMBL6762751 0.89 NR4A1 (0.44) FFAR1PLA2G2APLA2G5HTTALDH1A1
SCHEMBL6762901 0.88 ESR1 (0.44) ALDH1A1L3MBTL1
SCHEMBL6761222 0.88 NR4A1 (0.40) FFAR1PLA2G2APLA2G5ALDH1A1NR4A1
SCHEMBL6763908 0.87 MEN1 (0.48) FFAR1PLA2G2APLA2G5MEN1KMT2A
SCHEMBL6759839 0.86 TSHR (0.45) FFAR1PLA2G2APLA2G5ALDH1A1
SCHEMBL6761532 0.85 NR4A1 (0.48) FFAR1PLA2G2APLA2G5MEN1KMT2A
SCHEMBL6761449 0.84 NR4A1 (0.50) FFAR1PLA2G2APLA2G5MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040247698-A1 Erectile Dysfunction Treatment VALENZUELA CORTES CARMEN MARIA (CL) 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040247698-A1 Erectile Dysfunction Treatment PDE3A, PDE3B, PDE12 FFAR1 2283/4885PLA2G2A 2273/4885PLA2G5 1820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback